- Home
- ALKT vs CRSP Comparison
ALKT vs CRSP Comparison
Compare ALKT & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- CRSP
- Stock Information
- Founded
- ALKT 2007
- CRSP 2013
- Country
- ALKT United States
- CRSP Switzerland
- Employees
- ALKT N/A
- CRSP N/A
- Industry
- ALKT EDP Services
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALKT Technology
- CRSP Health Care
- Exchange
- ALKT Nasdaq
- CRSP Nasdaq
- Market Cap
- ALKT 3.3B
- CRSP 3.4B
- IPO Year
- ALKT 2021
- CRSP 2016
- Fundamental
- Price
- ALKT $31.14
- CRSP $47.87
- Analyst Decision
- ALKT Buy
- CRSP Buy
- Analyst Count
- ALKT 7
- CRSP 21
- Target Price
- ALKT $43.71
- CRSP $75.42
- AVG Volume (30 Days)
- ALKT 522.7K
- CRSP 2.7M
- Earning Date
- ALKT 02-27-2025
- CRSP 02-11-2025
- Dividend Yield
- ALKT N/A
- CRSP N/A
- EPS Growth
- ALKT N/A
- CRSP N/A
- EPS
- ALKT N/A
- CRSP N/A
- Revenue
- ALKT $315,562,000.00
- CRSP $37,314,000.00
- Revenue This Year
- ALKT $28.56
- CRSP $227.76
- Revenue Next Year
- ALKT $24.23
- CRSP $353.05
- P/E Ratio
- ALKT N/A
- CRSP N/A
- Revenue Growth
- ALKT 26.73
- CRSP N/A
- 52 Week Low
- ALKT $22.65
- CRSP $36.52
- 52 Week High
- ALKT $42.29
- CRSP $90.62
- Technical
- Relative Strength Index (RSI)
- ALKT 28.33
- CRSP 58.27
- Support Level
- ALKT $32.48
- CRSP $38.28
- Resistance Level
- ALKT $33.74
- CRSP $55.88
- Average True Range (ATR)
- ALKT 1.14
- CRSP 2.87
- MACD
- ALKT -0.30
- CRSP 1.07
- Stochastic Oscillator
- ALKT 4.40
- CRSP 54.50
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. Alkami Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency with the support of a proprietary, true cloud-based, multi-tenant architecture.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.